I-Mab Total Liabilities
I-Mab total liabilities. Based on the latest financial reports, I-Mab (IMAB) has total liabilities worth $18.50 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check I-Mab (IMAB) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of I-Mab (2017–2024)
Total liabilities of I-Mab from 2017 to 2024. This chart illustrates how I-Mab's total liabilities have evolved over time, based on quarterly financial data. Explore IMAB long-term investments to assets to see how much of total assets are deployed in long-term investments.
I-Mab Competitors by Total Liabilities
The table below lists competitors of I-Mab ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sinopec Shandong Taishan Petroleum Co Ltd
SHE:000554
|
China | CN¥314.56 Million |
|
Wuhan Langold Real Estate Co Ltd
SHE:002305
|
China | CN¥536.40 Million |
|
Zhejiang Tiantai Xianghe Industrial Co Ltd
SHG:603500
|
China | CN¥872.97 Million |
|
CHC Resources Corp
TW:9930
|
Taiwan | NT$5.29 Billion |
|
Anhui Ankai Automobile Co Ltd
SHE:000868
|
China | CN¥3.17 Billion |
|
Anshan Senyuan Road Bridge
SHE:300210
|
China | CN¥587.19 Million |
|
Bradespar S.A
SA:BRAP3
|
Brazil | R$48.40 Million |
|
GENERAL Elevator Co. Ltd.
SHE:300931
|
China | CN¥303.63 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down I-Mab's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see I-Mab assets under control.
Liquidity & Leverage Metrics
I-Mab Total Liabilities Ratios Explained
I-Mab total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how I-Mab's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for I-Mab (2017–2024)
The table below shows the annual total liabilities of I-Mab from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $11.52 Million | -98.71% |
| 2023-12-31 | $894.81 Million | -16.01% |
| 2022-12-31 | $1.07 Billion | +2.28% |
| 2021-12-31 | $1.04 Billion | +47.41% |
| 2020-12-31 | $706.65 Million | -81.27% |
| 2019-12-31 | $3.77 Billion | +13.25% |
| 2018-12-31 | $3.33 Billion | +151.37% |
| 2017-12-31 | $1.33 Billion | -- |
About I-Mab
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment o… Read more